← Equasens S. A. overview

Equasens S. A. vs Veeva Systems: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Equasens S. A. (EQS.PA)

Veeva Systems Inc Class A (VEEV)

Q3 2026
▲3▼1

Veeva beats Q2, wins big CRM deals, but valuation and departures pose risks

  • Q2 earnings beat and raised guidance Veeva beat Q2 estimates with $2.35 EPS and $928M revenue (up 17.6%), and raised full-year guidance on AI momentum. This strong financial performance supports a higher stock price.

    This is a new earnings report for Q2, not previously reported, and directly shows the company's financial health.

  • Major Vault CRM commitments Veeva won major Vault CRM commitments from Eli Lilly, Biogen, Regeneron, Amgen, and another top-20 biopharma. These wins validate Veeva's CRM strategy and expand its customer base.

    These new customer wins are not in earlier reports and show growing demand for Veeva's products.

  • New AI products and adoption New AI products (Falcon Safety, Study Builder Agent, Vault AI Agents) and growing adoption of OpenData, DQS, and Basics expand revenue potential. This reinforces Veeva's AI leadership.

    These are new product launches and adoption trends not covered in earlier reports, highlighting future growth drivers.

  • Executive departures and high valuation The president and chief customer officer depart in October, and Veeva's price-to-earnings ratio of 45 sits well above industry averages, leaving little margin for error if growth slows.

    These are new risks that could pressure the stock, balancing the positive news.

August 2026
▲3▼1

Veeva beats Q2, wins big CRM deals, but valuation and departures pose risks

  • Q2 earnings beat and raised guidance Veeva beat Q2 estimates with $2.35 EPS and $928M revenue (up 17.6%), and raised full-year guidance on AI momentum. This strong financial performance supports a higher stock price.

    This is a new earnings report for Q2, not previously reported, and directly shows the company's financial health.

  • Major Vault CRM commitments Veeva won major Vault CRM commitments from Eli Lilly, Biogen, Regeneron, Amgen, and another top-20 biopharma. These wins validate Veeva's CRM strategy and expand its customer base.

    These new customer wins are not in earlier reports and show growing demand for Veeva's products.

  • New AI products and adoption New AI products (Falcon Safety, Study Builder Agent, Vault AI Agents) and growing adoption of OpenData, DQS, and Basics expand revenue potential. This reinforces Veeva's AI leadership.

    These are new product launches and adoption trends not covered in earlier reports, highlighting future growth drivers.

  • Executive departures and high valuation The president and chief customer officer depart in October, and Veeva's price-to-earnings ratio of 45 sits well above industry averages, leaving little margin for error if growth slows.

    These are new risks that could pressure the stock, balancing the positive news.

Latest
▲4

Veeva's AI products and big pharma CRM wins drive growth

  • AI product launches expand Veeva's platform Veeva launched Falcon Safety, Study Builder Agent, and previewed Vault AI Agents, automating safety, clinical, and quality work. These new products deepen Veeva's role in drug development and could open new revenue streams, pushing the stock up.

    New AI products are a key growth driver and show Veeva is innovating beyond its core CRM.

  • Major biopharma companies adopt Vault CRM Biogen, Regeneron, Amgen, and another top-20 biopharma committed to Veeva's Vault CRM globally. These wins lock in long-term customers, increase switching costs, and support recurring revenue growth, lifting the stock.

    Customer wins are concrete evidence of demand and competitive strength, directly boosting revenue outlook.

  • Veeva's data and clinical platforms gain traction Servier selected Veeva OpenData across 80+ countries, and Veeva DQS cleaned data for over 1 million subjects. Over 175 biotechs now use Veeva Basics. These milestones show growing adoption of Veeva's broader data and clinical offerings, supporting future revenue.

    Adoption metrics for data and clinical products demonstrate expanding footprint beyond CRM.

  • AI threat fears ease, shorts unwind Veeva shares climbed in August as the anticipated AI disruption failed to materialize, and a hedge fund's forced unwind of short positions added a tailwind. This reduces a major overhang and supports the stock price.

    Removal of a key bearish narrative and short-covering directly lifted the stock.

▲3

Veeva beats Q2, raises guidance, and lands Eli Lilly as global CRM client

  • Eli Lilly commits to Veeva Vault CRM globally Eli Lilly will roll out Veeva's Vault CRM across its global operations. This is a big customer win: it shows top drugmakers will put critical sales software on Veeva's platform, which supports future subscription and services revenue.

    A major new customer commitment directly supports Veeva's growth outlook and is a core reason the stock is moving.

  • Q2 earnings and revenue beat estimates Veeva reported quarterly profit of $2.35 per share and revenue of $928 million, both above analyst expectations. Revenue grew 17.6% from a year earlier. Beating estimates shows the business is performing better than Wall Street expected, which pushes the stock up.

    The earnings beat is the main new financial event driving the stock higher this period.

  • Full-year guidance raised on AI momentum Management raised full-year revenue and profit guidance, citing AI as a new growth chapter. Vault CRM had its best quarter ever, and Veeva Falcon is accelerating. Higher guidance tells investors future results will be stronger than previously thought, lifting the stock.

    Raised guidance changes forward expectations, a key driver of the stock's move.

  • Leadership change and valuation caution Veeva's president and chief customer officer will leave in October, with a new sales and services head named. Also, the stock's price-to-earnings ratio of 45 is well above the industry average, leaving little room for error if growth slows.

    This is the real counterweight: a management change and high valuation could limit gains or add risk.

Q2 2026
▲3▼1

Veeva's AI Push and Earnings Beat Drive Gains, Fed Clouds Outlook

  • AI product launches and acquisition Veeva acquired Copli and launched Veeva Falcon MLR, an AI tool that automates medical, legal, and regulatory reviews, cutting manual work by over 70%. This expands Veeva's AI offerings and could boost future sales, pushing the stock up.

    This is a major new product and acquisition that directly drives VEEV's growth prospects.

  • Strong Q1 earnings and raised guidance Veeva beat earnings and revenue estimates, with subscription revenue up 15% and total revenue up 16%. The company raised full-year revenue guidance, signaling confidence. This positive financial performance supports a higher stock price.

    Earnings beat and guidance raise are key fundamental drivers of the stock's recent rise.

  • Fed signals no rate cuts, pressuring software stocks The Federal Reserve held rates steady and removed expectations for a 2026 cut, even hinting at a possible hike. Higher rates reduce the present value of future profits, which hurts software companies like Veeva. The stock fell 4.7% on the news.

    Monetary policy directly affects VEEV's valuation as a growth stock.

  • Nvidia CEO endorses AI's benefit to software Jensen Huang said AI will improve software companies, not replace them, naming Veeva as a potential winner. This endorsement boosts investor confidence in Veeva's AI strategy and long-term demand.

    High-profile support for AI in software can lift sentiment and demand for VEEV.

June 2026
▲3▼1

Veeva's AI Push and Earnings Beat Drive Gains, Fed Clouds Outlook

  • AI product launches and acquisition Veeva acquired Copli and launched Veeva Falcon MLR, an AI tool that automates medical, legal, and regulatory reviews, cutting manual work by over 70%. This expands Veeva's AI offerings and could boost future sales, pushing the stock up.

    This is a major new product and acquisition that directly drives VEEV's growth prospects.

  • Strong Q1 earnings and raised guidance Veeva beat earnings and revenue estimates, with subscription revenue up 15% and total revenue up 16%. The company raised full-year revenue guidance, signaling confidence. This positive financial performance supports a higher stock price.

    Earnings beat and guidance raise are key fundamental drivers of the stock's recent rise.

  • Fed signals no rate cuts, pressuring software stocks The Federal Reserve held rates steady and removed expectations for a 2026 cut, even hinting at a possible hike. Higher rates reduce the present value of future profits, which hurts software companies like Veeva. The stock fell 4.7% on the news.

    Monetary policy directly affects VEEV's valuation as a growth stock.

  • Nvidia CEO endorses AI's benefit to software Jensen Huang said AI will improve software companies, not replace them, naming Veeva as a potential winner. This endorsement boosts investor confidence in Veeva's AI strategy and long-term demand.

    High-profile support for AI in software can lift sentiment and demand for VEEV.

▲3▼1

Veeva's AI Push and Earnings Beat Drive Gains, Fed Clouds Outlook

  • AI product launches and acquisition Veeva acquired Copli and launched Veeva Falcon MLR, an AI tool that automates medical, legal, and regulatory reviews, cutting manual work by over 70%. This expands Veeva's AI offerings and could boost future sales, pushing the stock up.

    This is a major new product and acquisition that directly drives VEEV's growth prospects.

  • Strong Q1 earnings and raised guidance Veeva beat earnings and revenue estimates, with subscription revenue up 15% and total revenue up 16%. The company raised full-year revenue guidance, signaling confidence. This positive financial performance supports a higher stock price.

    Earnings beat and guidance raise are key fundamental drivers of the stock's recent rise.

  • Fed signals no rate cuts, pressuring software stocks The Federal Reserve held rates steady and removed expectations for a 2026 cut, even hinting at a possible hike. Higher rates reduce the present value of future profits, which hurts software companies like Veeva. The stock fell 4.7% on the news.

    Monetary policy directly affects VEEV's valuation as a growth stock.

  • Nvidia CEO endorses AI's benefit to software Jensen Huang said AI will improve software companies, not replace them, naming Veeva as a potential winner. This endorsement boosts investor confidence in Veeva's AI strategy and long-term demand.

    High-profile support for AI in software can lift sentiment and demand for VEEV.